Henrijette Richter

Henrijette Richter is one of their managing partners and an active member of the Capital Funds team, their flagship fund dedicated to early-stage biotechs and MedTechs.

She joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitrase Therapeutics, Nodthera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics.

Henrijette was attracted by Sofinnova Partners’ focus on a positive, consensus-oriented environment and its philosophy of investing in people.

Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris).

Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Mozart Therapeutics

Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.


Industries

Employees

1-10

Links